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United KingdomBackground: The mechanism underlying nonsevere and severe
asthma remains unclear, although it is commonly associated
with increased airway smooth muscle (ASM) mass. Long
noncoding RNAs (lncRNAs) are known to be important in
regulating healthy primary airway smooth muscle cells
(ASMCs), whereas changed expression has been observed in
CD8 T cells from patients with severe asthma.
Methods: Primary ASMCs were isolated from healthy subjects
(n 5 9) and patients classified as having nonsevere (n 5 9) or
severe (n 5 9) asthma. ASMCs were exposed to dexamethasone
and FCS. mRNA and lncRNA expression was measured by
using a microarray and quantitative real-time PCR.
Bioinformatic analysis was used to examine relevant biological
pathways. Finally, the lncRNA plasmacytoma variant
translocation 1 (PVT1) was inhibited by transfection of primary
ASMCs with small interfering RNAs, and the effect on ASMC
phenotype was examined.
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http://dx.doi.org/10.1016/j.jaci.2016.06.014dexamethasone and FCS, and these were associated with
biological pathways that might be relevant to the pathogenesis
of asthma, including cellular proliferation and pathways
associated with glucocorticoid activity. We also observed a
significant change in lncRNA expression, yet the expression of
only one lncRNA (PVT1) is decreased in patients with
corticosteroid-sensitive nonsevere asthma and increased in
patients with corticosteroid-insensitive severe asthma.
Subsequent targeting studies demonstrated the importance of
this lncRNA in controlling both proliferation and IL-6 release in
ASMCs from patients with severe asthma.
Conclusions: lncRNAs are associated with the aberrant
phenotype observed in ASMCs from asthmatic patients.
Targeting PVT1 might be effective in reducing airway
remodeling in asthmatic patients. (J Allergy Clin Immunol
2016;nnn:nnn-nnn.)
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Asthma is characterized by airflow obstruction and chronic
airway inflammation and remodeling.1 Airway smooth muscle
(ASM) hyperplasia and hypertrophy lead to increased airway
wall thickening and airway narrowing, contributing to airway
obstruction and inflammation. Epigenetic mechanisms are key
regulators of ASM function.2 We have reported that the aberrant
phenotype of airway smooth muscle cells (ASMCs) from
asthmatic patients is under the negative regulation of the cyclin in-
hibitors p21WAF1 and p27kip1, which are controlled bymicroRNA-
221.3 Furthermore, using a transcriptomics-based approach, we
identified potential microRNA (miRNA) targets and pathways
in activated human ASMCs and observed changes in expression
of long noncoding RNAs (lncRNAs), including natural antisense,
pseudogenes, intronic lncRNAs, and intergenic lncRNAs.4
Having reported results with healthy (or nonasthmatic) ASMCs
in 2014,4 we now report on the asthmatic ASMCs that were studied
at the same time. Specifically, we report on the differential expres-
sion of mRNAs and lncRNAs in ASMCs isolated from patients
with nonsevere and severe asthma and treated with dexamethasone
before subsequent activation with the growth medium FCS. We
have then focused on the only lncRNA found to be decreased in
expression in patients with corticosteroid-sensitive nonsevere
asthma and increased in expression in patients with
corticosteroid-insensitive severe asthmatics, plasmacytoma variant
translocation 1 (PVT1), and performed targeting studies to examine1
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induced by the combination of TGF-b and FCS.
METHODS
Full methodology is available in theMethods section in this article’s Online
Repository at www.jacionline.org.
Subject selection and ASMC culture
Primary ASMCs from healthy subjects, patients with nonsevere asthma,
and patients with severe asthma were treated, as described previously,4-7 and
proliferation rates, cellular viability, and IL-6 release (see Fig E1 in this
article’s Online Repository at www.jacionline.org), were all comparable to
our previous studies.1-3 Patients’ characteristics are shown in Table I.
RNA extraction
RNA was extracted with the mirVana miRNA isolation kit, as previously
described.3-7
Microarray analysis
lncRNA andmRNA expression was determined by using Agilent SurePrint
G3 Human GE microarrays (Agilent Technologies, Santa Clara, Calif),
according to the manufacturer’s instructions, and as previously described.4
Total RNA samples (50 ng) used in lncRNA and mRNA microarrays were
initially labeled with Spike-In control A (for cyanine 3–cytidine triphosphate)
or B (for cyanine 5–CTP). Labeled samples were then used for cDNA synthe-
sis by using the cDNA Master Mix (Agilent Technologies) and incubated for
2 hours at 408C, followed by 15 minutes at 708C to inactivate the Affinity-
Script enzyme. The synthesized cDNA was then used for coding RNA
(cRNA) synthesis and amplification by using the Transcription Master Mix
with either cyanine 3 or cyanine 5 and incubated at 408C for 2 hours. Labeled
and amplified RNA was then purified with the RNeasy Mini Kit (Qiagen,
Hilden, Germany) and quantified with the NanoDrop Spectrophotometer’s
Microarray Measurement function (NanoDrop, Wilmington, Del). The
cyanine 3 or cyanine 5 concentrations and the cRNA concentration were
used to calculate the yield (in micrograms) and specific activity (in picomoles
of cyanine 3 or cyanine 5 per microgram of cRNA) of each sample. For each
microarray reaction, 300 ng of cyanine 3–labeled and 300 ng of cyanine
5–labeled linearly amplified cRNA samples were mixed and incubated
together with fragmentation buffer for 30 minutes, followed by addition of hy-
bridization buffer. Samples were loaded onto SurePrint G3 (83 60 K) micro-
array slides (Agilent Technologies) and hybridized at 658C for 17 hours at
10 rpm by using Agilent’s Hybridization oven and SureHyb chamber. The mi-
croarrays were then disassembled and washed in GE Wash Buffer 1 (Agilent
Technologies) for 60 seconds at room temperature, followed by GE Wash
Buffer 2 for 60 seconds at 378C, followed by an acetonitrile wash (10 seconds
at room temperature) and a final wash in stabilization and drying solution for
30 seconds at room temperature, to improve microarray results by preventing
ozone-mediated fluorescent signal degradation. The microarrays were
scanned with the Agilent Microarray Scanner G2565BA by using the profile
for 2-color microarrays (AgilentG3_GX_2Color) at 5-mm resolution (dye
channel, Red&Green; scan area, 61 3 21.6 mm).After normalization against internal controls provided within the labelling
kits, probes with background expression (signal value of mRNA < 4.5) were
removed. The threshold of background expression was determined by using
samples that were processed but contained noRNA. Because initial analysis of
mRNA and lncRNA between baseline and FCS-treated cells or dexametha-
sone plus FCS–treated cells showed none that produced a false discovery rate
of less than 0.1, differential expression (P value) was determined by using 3-
wayANOVAwith the PartekGenomics Suite.We report changes in expression
at a P value of less than .05.Pathway analysis
Differentially expressed mRNAs from each data set were further analyzed
by using the bioinformatics software Ingenuity Pathway Analysis application
(www.ingenuity.com). A core functional analysis was performed to identify
canonical pathways, predicted upstream regulators, and gene networks most
associated significantly with the differentially expressed mRNAs.
The significance of the association of a given canonical pathway with the
differentially expressedmRNAswasmeasured in 2ways: (1) based on the ratio
of the number of differentially expressedmRNAs in the data set that mapped to
the canonical pathway divided by the total number of genes that map to the
canonical pathway and (2) by using the Fisher exact test to calculate a P value
for the association between the mRNA and network/canonical pathway.Quantitative PCR measurement of miRNA and
mRNA expression
lncRNA and mRNA expression was measured, as previously described.4Transfection with small interfering RNAs that
target PVT1
ASMCs were transfected, as previously described.3,5,8 Small interfering
RNAs (siRNAs) designed to target PVT1 and IL6 were purchased from Am-
bion/Applied Biosystems, Waltham, Mass. ASMCs were transfected with
PVT1 inhibitor (30, 100, or 300 nmol/L), IL6 inhibitor (100 nmol/L), or
SilencerNegativeControl #1 (100 nmol/L) and no siRNA (mock transfection).Data and statistical analysis
Data were analyzed with GraphPad Prism software, version 5.03 (Graph-
Pad Software, La Jolla, Calif). Data were not normally distributed (as assessed
by using the Kolmogorov-Smirnov test), and therefore groups were compared
with the Dunn nonparametric test. All data are expressed as means 6 SEMs.RESULTS
mRNAs are differentially expressed between
ASMCs from patients with nonsevere and those
with severe asthma and are responsible for
different pathway activation
Comparison of mRNA expression in ASMCs from healthy
subjects and patients with nonsevere or severe asthma showed
differential expression (P < .05) of different gene sets depending
on the status of the cells being at a ‘‘baseline’’ state after stimula-
tion with FCS and those pretreated with dexamethasone before
stimulation with FCS. Full gene lists are shown in Tables
E1-E9 in this article’s Online Repository at www.jacionline.org.
To identify the pathways in which these mRNAs are involved,
we analyzed each data set by using the bioinformatics software
application Ingenuity Pathway Analysis. At baseline, those
mRNAs that were increased in expression compared with ASMCs
from healthy subjects in the nonsevere asthma cohort are
proposed to be important in hydrolase activity. Those decreased
TABLE I. Characteristics of subjects
Nonasthmatic
patients
Patients with
nonsevere asthma
Patients with
severe asthma
No. 9 9 9
Age (y) 36.4 6 12.7 42.4 6 16.2 48.9 6 11
Sex (male/female) 7/2 6/4 3/6
Asthma duration (y) NA 22.2 6 16.8 25.6 6 13.2
Inhaled corticosteroid dose (mg of BDP equivalent) NA 580 6 576.9 1688.9 6 176.4
Atopy (no.)* 0 8 8
Receiving oral corticosteroids (no.) 0 0 7
FEV1 (L) 4.02 6 0.48 2.81 6 0.71 2.7 6 0.82
FEV1 (% predicted) 104.23 6 7.28 84.68 6 12.31 80.48 6 12.34
FEV1/FVC ratio (%) 78.79 6 5.98 69.87 6 9.27 63.98 6 9.68
b-Agonist reversibility (%) NA 12.3 6 11.9 19.54 6 14.56
PC20 (mg/mL) >16 0.69 6 0.64 0.2 6 0.39
Data are shown as means 6 SEMs.
BDP, Beclomethasone dipropionate; FVC, forced vital capacity; NA, not available.
*Defined as positive skin prick test responses to 1 or more common aeroallergens.
Measured as percentage increase in FEV1 after 400 mg of salbutamol.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
AUSTIN ET AL 3in expression are involved in the extracellular matrix, and the
whole profile is important for cellular assembly (Fig 1, A). Inter-
estingly, hydrolase activity is known to be important for calcium
signaling in ASM,9 and the extracellular matrix is involved in
asthmatic airway remodeling.10 In the ASMCs from the patients
with severe asthma, these profiles changed to an increase in genes
necessary for arachidonic acidmetabolism and a decrease in those
required for multicellular organismal process, and the whole pro-
file is involved in gene expression and organ morphology. Once
again, this follows our current knowledge of ASM function and
the fact that arachidonic acid induces calcium influx in human
airway smooth muscle, which has been proposed to contribute
to increased influx in asthmatic patients,11 and previous methyl-
ation profiling of the bronchial mucosa of asthmatic patients
has demonstrated a positive relationship to atopy for the multicel-
lular organismal process.12 After stimulation with FCS, those
mRNAs increased in expression in the patients with nonsevere
ASM are associated with the intracellular organelle lumen, those
decreased are involved in single-organism development, and
together the profile is important in the inflammatory response
that is well documented in human ASM (Fig 1, B).13 In ASMCs
from patients with severe asthma, thosewith increased expression
are involved in respiratory tube development, and those with
decreased expression are involved in signaling. However,
together, the mRNAs are proposed to be important in patients
with immunologic disease, which helps explain how ASM is
important for immunomodulation in acute exacerbations of
airway disease, including asthma.14 When these same ASM co-
horts were pretreated with dexamethasone, before stimulation
with FCS (Fig 1,C), those pathways activated in ASMCs from pa-
tients with nonsevere asthma were associated with glucocorticoid
activity, such as macrophage activation, the inflammatory
response,15 and phospholipase activity.16 However, ASMCs
from patients with severe asthma responded by activating genes
associated with cellular growth and proliferation, a phenotype
well documented as being aberrant.3-6
Levels of NAV2, NFIB, PTGIS, CHI3L1, NOVA1, PTPRD, IL6,
PGM5, and NNATwere selected to be verified by means of quan-
titative RT-PCR (Fig 1, D). For each of these, FCS caused a sig-
nificant increase in expression in ASMCs from both patients with
nonsevere and those with severe asthma (P <.05). Pretreatment ofASMCs from patients with nonsevere asthma with dexametha-
sone inhibited this increase in expression in all mRNAs, apart
from NAV2. In ASMCs from patients with severe asthma, dexa-
methasone caused a further increase in NAV2 and PTGIS expres-
sion (P < .01); in all other instances dexamethasone only slightly
inhibited the FCS-induced mRNA expression to levels that were
not comparable with ASMCs from patients with nonsevere
asthma.lncRNAs are differentially expressed between
ASMCs from patients with nonsevere and those
with severe asthma
We have previously shown that more than 30 lncRNAs are
increased in expression in healthy primary ASMCs after treat-
ment with dexamethasone and stimulation with FCS.4 Hence to
identify novel lncRNAs in ASMCs from asthmatic patients, we
used ENSEMBLE (www.ensembl.org/index.html) to determine
the genomic position of those probe sets from the microarray
that did not match known protein-coding genes.
At baseline, 21 lncRNAs were differentially expressed in
ASMCs from patients with nonsevere asthma (15 increased and
6 decreased) when compared with healthy subjects (see Table E10
in this article’s Online Repository at www.jacionline.org).
ASMCs from patients with severe asthma differentially expressed
19 lncRNAs (13 increased and 6 decreased) when compared with
healthy subjects (see Table E11 in this article’s Online Repository
at www.jacionline.org).4 Interestingly, 4 lncRNAs were altered in
expression in both disease phenotypes (RP5-1158E12.3,
FKBP1A-SDCBP2, LINC00472, and PVT1), and PVT1 was also
differentially expressed in ASMCs from healthy subjects.4 After
stimulation with FCS, ASMCs from patients with nonsevere
asthma expressed a completely different set of lncRNAs (15
increased and 16 decreased), with the exception of PVT1 and
RP11-141M1 (see Table E12 in this article’s Online Repository
at www.jacionline.org), and treatment of the same cells with
dexamethasone, before said stimulation resulted in an increase
in expression of 60 lncRNAs, and a decrease in 19 (see Table E13
in this article’s OnlineRepository atwww.jacionline.org). A similar
pattern was observed in FCS-stimulated ASMCs from patients with
severe asthma; of the 32 lncRNAs that changed in expression, only
FIG 1. Venn diagrams showing pathway analysis of differentially expressedmRNAs in ASM from asthmatic
patients. A-C, Pathway analysis showing intergroup comparisons at baseline (Fig 1, A), after stimulation
with FCS (2.5%; Fig 1, B), and after stimulation with FCS (2.5%) plus TGF-b (1 ng/mL; Fig 1, C). Data represent
9 members of each patient type. D, Expression of 9 mRNAs was confirmed by using TaqMan RT-PCR to vali-
date the array data. Bars represent means 6 SEMs from 9 primary ASMC donors. *P < .05, **P < .01, and
***P < .001.
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the baseline ASMCs from patients with nonsevere asthma (see
Table E14 in this article’s Online Repository at www.jacionline.
org). Furthermore, when ASMCs from patients with severe asthma
were treated with dexamethasone before subsequent stimulation
with FCS, the number of differentially expressed lncRNAs doubled
(36 increased and 38 decreased in expression, see Table E15 in this
article’s Online Repository at www.jacionline.org).
Of those lncRNAs that were expressed in ASMCs from
asthmatic patients, only PVT1 was found to be decreased in
expression in the patients with corticosteroid-sensitive nonsevere
asthma and increased in expression in patients with
corticosteroid-insensitive severe asthma (see Tables E10 and
E11). Thereforewe further examined the function of this lncRNA.Effect of FCS and TGF-b on PVT1 lncRNA
expression in ASMCs from asthmatic patients
We have previously demonstrated that combined stimulation
with FCS (2.5%) and TGF-b (1 ng/mL) is required to induce adifferential response in both cellular proliferation and cytokine
release in ASMCs from asthmatic patients.3,5 To determine the
potential role of PVT1 in this proliferative and inflammatory
response, we examined the time course of its expression in the
presence of FCS and TGF-b. FCS plus TGF-b did not change
the expression of PVT1 up to 24 hours in ASMCs from healthy
subjects (Fig 2, A), whereas at 24 hours, there was a significant
reduction in the expression of PVT1 in ASMCs from patients
with nonsevere asthma (P <.01 vs unstimulated control ASMCs).
Furthermore, FCS plus TGF-b led to an approximately 3-fold in-
crease (P < .01 vs unstimulated control ASMCs) in PVT1 expres-
sion, which reached a plateau at 3 hours in ASMCs from patients
with severe asthma and remained increased at 24 hours (Fig 2, A).
At 24 hours, dexamethasone had no effect on PVT1 expression
in ASMCs from healthy subjects (Fig 2, B). However, the FCS
plus TGF-b–induced reduction of PVT1 expression in ASMCs
from patients with nonsevere asthma returned to basal levels in
the presence of dexamethasone (P <.01). Furthermore, dexameth-
asone alone increased PVT1 expression in ASMCs from patients
with severe asthma (approximately 4-fold, P < .001), and when
FIG 2. Effect of dexamethasone and FCS plus TGF-b on PVT1 lncRNA
expression in ASMCs from asthmatic patients. A, FCS plus TGF-b–induced
PVT1 lncRNA expression was measured by using quantitative RT-PCR over
1, 3, 6, and 24 hours. B, Dexamethasone (Dex) and FCS plus TGF-b–induced
PVT1 expression was measured by using quantitative RT-PCR at 24 hours.
Points/bars represent means 6 SEMs of 9 ASMC donors. **P < .01 and
***P < .001. ## P < .01.
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an even greater increase in expression was observed (approxi-
mately 8-fold, P < .001; Fig 2, B).Inhibition of PVT1 with siRNAs on ASMC
proliferation and IL-6 release
To elucidate the role of PVT1, we examined the action of
siRNA-mediated inhibition of PVT1 on dexamethasone-
exposed, FCS plus TGF-b–induced bromodeoxyuridine (BrdU)
incorporation and IL-6 release. As previously reported,3,5 a sig-
nificant increase in BrdU incorporation and IL-6 release was
observed in both healthy subjects and patients with severe asthma
after stimulation with FCS plus TGF-b (P <.001 vs unstimulated
control ASMCs; Fig 3, C-F). Dexamethasone inhibited BrdU
incorporation and IL-6 release in the healthy ASMCs but had
no effect on BrdU incorporation in ASMCs from patients with se-
vere asthma and a limited effect on IL-6 release (Fig 3, C-F).
These results also demonstrate the relative corticosteroid insensi-
tivity of the cells from patients with severe asthma compared with
those from healthy subjects with respect to BrdU incorporation
and IL-6 release.
Transfectionwith Amaxa electroporationwith siRNAs designed
to target PVT1 (300 nmol/L) knocked down expression of PVT1 in
ASMCs fromhealthy subjects both at baseline and after stimulation
with FCS plus TGF-b (P <.01; Fig 3,A).When the same cells were
exposed to dexamethasone before stimulation with FCS plus TGF-
b, a reduction was still observed, although not to the same level aswithout dexamethasone (P < .05). When PVT1 was targeted with
siRNAs in ASMCs from patients with severe asthma, the FCS
plus TGF-b– and dexamethasone plus FCS plus TGF-b–induced
PVT1 expression was returned to basal levels (Fig 3, B).
Knocking down PVT1 had no effect on BrdU incorporation
induced by FCS plus TGF-b in either cohort of ASMCs (Fig 3,
C andD). However, PVT1 knockdown increased BrdU incorpora-
tion in ASMCs from patients with severe asthma when they were
exposed to dexamethasone before stimulation with FCS plus
TGF-b (P < .01 vs dexamethasone plus FCS plus TGF-b; Fig 3,
D). Furthermore, siRNA-targeted inhibition of PVT1 both re-
sulted in an increase in FCS plus TGF-b–induced IL-6 release
(P < .01 vs FCS plus TGF-b) and reversed the inhibitory action
of dexamethasone in ASMCs from healthy subjects (P < .01 vs
dexamethasone plus FCS plus TGF-b; Fig 3, E). This suggests
that inhibiting expression of PVT1 increases corticosteroid
insensitivity in ASMCs; however, there was no effect observed
on IL-6 release in ASMCs from patients with severe asthma
when PVT1 was targeted, although this might be because of
IL-6 release already being at maximal levels (Fig 3, F).
A nontargeting negative control (30-300 nmol/L) demonstrated
no effect on either BrdU incorporation or IL-6 release in either
cohort, as previously shown (data not shown).3,5,8 To demonstrate
evidence of efficient transfection, concurrent studies were per-
formed to examine the effect of siRNAs (100 nmol/L) targeted
to IL6 mRNA. A reduction in IL-6 release induced by FCS plus
TGF-b stimulation in ASMCs from healthy subjects (P < .001)
and those from patients with severe asthma (P < .01) was
observed, as previously described (see Fig E2, A and B, in this ar-
ticle’s Online Repository at www.jacionline.org).3,8 Furthermore,
to demonstrate that electroporation had no adverse effect
on cellular viability, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assays were performed both before
(see Fig E2, C and D) and after (see Fig E2, E and F) stimulation
with FCS plus TGF-b. In either situation, transfection by using
Amaxa electroporation had no effect on cellular viability.Effect of PVT1 inhibition on IL6mRNA expression in
ASMCs from asthmatic patients
In a similar pattern to that seen in the increasing IL-6 protein
release induced by FCS plus TGF-b in these ASMCs,3 IL6mRNA
expression is increased in healthy cells (approximately 15-fold),
greater still in cells from patients with nonsevere asthma (approx-
imately 20-fold), and increased to the highest degree in cells from
patients with severe ASMCs (approximately 45-fold) when these
cells are stimulated with FCS plus TGF-b (P < .01 vs unstimu-
lated control; Fig 4, A). Incubation with dexamethasone before
stimulation with FCS plus TGF-b resulted in inhibition of IL6
mRNA expression in ASMCs from healthy subjects and patients
with nonsevere asthma (P < .001 and P < .01, respectively), with
no significant effect in ASMCs from patients with severe asthma
(Fig 4, A).
The effect of PVT1 targeting by siRNAs on IL6 mRNA was
then examined. In ASMCs from healthy subjects, the FCS plus
TGF-b–induced expression of IL6 was similar to that observed
in Fig 4, A, when the cells were either mock transfected or trans-
fected with 100 nmol/L of negative control siRNA (Fig 4, C).
When the healthy ASMCs were transfected with an siRNA de-
signed to target IL6 mRNA, the expression of this mRNA was
almost completely attenuated (P < .001; Fig 4, C). However,
FIG 3. Effect of targeting PVT1 with siRNAs on IL-6 release and BrdU incorporation in ASMCs from healthy
subjects and patients with severe asthma. A and B, PVT1 lncRNA expression was measured by using RT-
PCR after ASM from healthy subjects and patients with severe asthma was transfected with siRNA
(300 nmol/L), which was designed to target PVT1. C-F, BrdU incorporation (Fig 3, C and D) and IL-6 release
(Fig 3, E and F) were measured by using the BrdU ELISA and DuoSet ELISA, respectively, at 8 days. Bars/
points represent means 6 SEMs of 9 ASMC donors. */#P < .05, ##/11P < .01, and ***/###P < .001. Dex,
Dexamethasone.
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inhibited in these ASMCs with 300 nmol/L siRNA, a significant
increase in IL6 mRNA expression was observed when the cells
were stimulated with FCS plus TGF-b (P < .05; Fig 4, C). Addi-
tion of dexamethasone before FCS plus TGF-b resulted in adecrease in IL6 mRNA levels in the mock and negative siRNA-
transfected cells, and IL-6 siRNA transfection resulted in inhibi-
tion of IL6 mRNA expression (Fig 4, C).
IL6 mRNA expression was similarly affected by the different
transfectionvariables in ASMCs from patients with severe asthma
FIG 4. Effect of targeting PVT1 with siRNAs on IL6 and c-MYC mRNA in ASMCs from healthy subjects and
patients with severe asthma. A and B, IL6 and c-MYCmRNA expression was measured by using RT-PCR af-
ter exposure to dexamethasone (Dex; 1027 mol/L) and stimulation with FCS (2.5%) plus TGF-b (1 ng/mL) for
24 hours. C-F, ASMCs from healthy subjects and patients with severe asthma were transfected with siRNAs
designed to target PVT1. Also, the expression of IL6 (Fig 4, C and E) and c-MYC (Fig 4, D and F) mRNA was
measured by using RT-PCR. Bars represent means 6 SEMs of 9 ASMC donors. #P < .05, **/##/11P < .01,
and ***/###/111P < .001.
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FIG 5. A and B, Potential mechanisms for PVT1 contribution to ASMC proliferation and IL-6 release in asth-
matic patients. Dex, Dexamethasone; FCS, fetal calf serum; TGF-b, transforming growth factor-beta.
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tive control siRNA had no effect on IL6mRNAexpression. Trans-
fecting with an siRNA designed to target IL6 inhibited IL6mRNA
expression (Fig 4, E). However, inhibiting the expression of PVT1
with siRNAs reduced IL6 mRNA expression after stimulation
with FCS plus TGF-b, both with and without exposure to dexa-
methasone (P < .001; Fig 4, E).Effect of PVT1 inhibition on c-MYCmRNA in ASMCs
from asthmatic patients
PVT1 is transcriptionally activated by the oncogene c-MYC,4,17
and we have previously reported that c-MYC is important in
controlling ASMC proliferation but not cytokine release.5Therefore we examined the effect of targeting PVT1with siRNAs
on c-MYC mRNA expression. Stimulation with FCS plus TGF-b
induced an increase in c-MYCmRNA expression in ASMCs from
patients with severe asthma (P < .01), with no effect seen in
ASMCs from healthy subjects or patients with nonsevere asthma
(Fig 4, B). Exposure of ASMCs from patients with severe asthma
to dexamethasone, either on its own or before stimulation with
FCS plus TGF-b, resulted in a larger increase in c-MYC mRNA
expression (both P < .001; Fig 4, B).
Transfecting siRNAs designed to target PVT1 (300 nmol/L)
knocked down expression of c-MYC in healthy ASMCs both at
baseline and after stimulation with FCS plus TGF-b (P < .01;
Fig 4, D). When PVT1 was targeted with siRNAs in ASMCs
from patients with severe asthma, the FCS plus TGF-b– and
J ALLERGY CLIN IMMUNOL
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sion was returned to basal levels (Fig 4, F).
In summary, these results show that in primary ASMCs from
nonasthmatic subjects, inhibiting the endogenous expression of
PVT1 results in reversal of the inhibitory action of dexamethasone
on FCS plus TGF-b–induced IL6 mRNA expression and protein
release. Furthermore, in ASMCs from patients with severe
asthma, dexamethasone increases PVT1 expression, and inhibi-
tion of this with siRNAs results in an increase in FCS plus
TGF-b–induced cellular proliferation through targeting of the
transcription factor c-MYC.DISCUSSION
Using a transcriptomics-based approach, we examined the
expression of RNAs (mRNA, miRNA, and lncRNA) in primary
ASMCs isolated from nonasthmatic subjects, patients with non-
severe asthma, and patients with severe asthma. We published the
results of the nonasthmatic subjects in 2014,4 and now, after some
additional functional studies, report on the patients with nonse-
vere and severe asthma.
Of the mRNAs we examined, we found that the mRNA profile
differentially regulated in ASMCs from patients with nonsevere
asthma is important in ASMC calcium signaling,9 airway remod-
eling,10 the inflammatory response,13 and glucocorticoid activ-
ity.15,16 Interestingly, the mRNA profile in ASMCs from
patients with severe asthma appears to be important in increased
calcium influx in the smooth muscle,11 atopy,12 and possible im-
munomodulation in patients with acute exacerbations of airway
disease, including asthma.14 Furthermore, when confirming our
array results using RT-PCR, we described mRNAs with expres-
sion that has previously been shown to be increased in response
to dexamethasone (NAV2)18 to regulate cell viability, cell growth,
cellular proliferation, and/or airway remodeling (NFIB, NOVA1,
PTPRD, and PGM5)19-22 and those acting as potential tumor sup-
pressors in patients with lung carcinoma (PTPRD andNNAT).23,24
Furthermore, we describe a large increase in CHI3L1 expression,
which has not only been reported in a number of patients with in-
flammatory diseases and cancer but also has been implicated in
asthmatic patients, with the discovery of an allele that doubles
the risk.25 However, PTGIS is the only one of these mRNA targets
to have been associated with ASM and can induce both broncho-
dilation and reverse ASMC remodeling in a mouse model of
asthma.26
We also measured the expression of lncRNAs in our patient
cohorts. A large number of lncRNAs were differentially ex-
pressed under all situations (baseline, corticosteroid treatment,
and mitogen stimulation). Interestingly, only PVT1 was found to
be decreased in ASMCs from patients with nonsevere asthma and
increased in ASMCs from patients with severe asthma, and there-
forewe performed functional studies on this lncRNA in ourmodel
of asthmatic hyperproliferation and corticosteroid insensitivity.3,5
The action of PVT1 in our ASMCs from asthmatic patients was
complex. As such, we have proposed a figure that shows potential
mechanisms for PVT1 in ASMC proliferation and IL-6 release
(Fig 5). In ASMCs from nonasthmatic healthy subjects, TGF-b
plus FCS induces IL6 mRNA expression, which translates into
IL-6 protein release. Interestingly, the addition of dexamethasone
results in an increase in expression of PVT1, which, when in-
hibited by siRNAs (Fig 5, A), induces greater IL6 mRNA expres-
sion and more IL-6 protein release. In ASMCs from patients withsevere asthma, TGF-b plus FCS not only induces IL6 mRNA
expression and protein release but also PVT1 expression. The ef-
fect of dexamethasone was the same, and when we inhibited
PVT1 in these ASMCs with siRNAs (Fig 5, B), a decrease in
IL6 mRNA and IL-6 protein release was observed, along with a
concurrent increase in cellular proliferation. The mechanism of
action of PVT1 in human primary ASM is clearly complex.
Very little is known about the role of PVT1 in human pathologies.
PVT1 is frequently expressed in patients with numerous cancers
(including lung)27-31 and diabetes.32-34 Furthermore, targeting
of PVT1 in these pathologies has been shown to have a range of
effects, including decreasing proliferation and increasing
apoptosis,28,35 decreasing resistance to gemcitabine (a chemo-
therapy drug),36 and regulation of genes and proteins involved
in ECM deposition.32 For the first time, we have demonstrated
the novel way in which targetingPVT1 in human primary ASMCs
can affect phenotype.
The variable mechanism of action of PVT1 could simply be a
consequence of different cells, tissues, and pathologies examined;
however, it might also be due to the action and configuration of
PVT1 itself. PVT1 is a downstream target of c-MYC that targets
and binds PVT1, driving its transcription.17 We show that in our
severe asthmatic ASMC cohorts, dexamethasone increases
PVT1 expression, and inhibition of this results in an increase in
FCS plus TGF-b–induced cellular proliferation, possibly by tar-
geting of c-MYC.
Finally, PVT1 is unlikely to be the only noncoding RNA
(ncRNA) acting in our ASMC model. We have previously re-
ported on the role of miRNAs in these cells after stimulation
with TGF-b plus FCS,3 and now it is known that PVT1 can ex-
press a cluster of 6 miRNAs, such as miR-1207-5p (which we dis-
cussed previously4). Although these ncRNAs are coexpressed,
regulation of miR-1207-5p expression by TGF-b is independent
of PVT1.33
In conclusion, we have demonstrated a large difference in
ncRNA expression profiles (including miRNAs and lncRNAs) in
primary human ASMCs from patients with nonsevere and severe
asthma and the differential effects of adding corticosteroids and
mitogen. Furthermore, we have found that PVT1 regulates both
IL-6 release and proliferation in ASMCs from patients with se-
vere asthma.
Key messages
d Severe asthma is a worldwide health issue that is mostly
unresponsive to existing therapy.
d lncRNAs are differentially expressed between ASMCs
from patients with nonsevere and severe asthma.
d Targeting of the lncRNA PVT1 can reduce increased
cellular proliferation and IL-6 release from ASMCs in pa-
tients with severe asthma.
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